These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7655816)

  • 1. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
    Williams DM; Carter KC; Baillie AJ
    J Drug Target; 1995; 3(1):1-7. PubMed ID: 7655816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.
    Carter KC; Dolan TF; Alexander J; Baillie AJ; McColgan C
    J Pharm Pharmacol; 1989 Feb; 41(2):87-91. PubMed ID: 2568434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis.
    Hunter CA; Dolan TF; Coombs GH; Baillie AJ
    J Pharm Pharmacol; 1988 Mar; 40(3):161-5. PubMed ID: 2899143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
    Pal S; Ravindran R; Ali N
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic control of drug-induced recovery from murine visceral leishmaniasis.
    Carter KC; Baillie AJ; Alexander J
    J Pharm Pharmacol; 1993 Sep; 45(9):795-8. PubMed ID: 7903366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate.
    Collins M; Carter KC; Baillie AJ
    Ann Trop Med Parasitol; 1992 Feb; 86(1):35-40. PubMed ID: 1319700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
    Roberts WL; Hariprashad J; Rainey PM; Murray HW
    Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate.
    Baillie AJ; Coombs GH; Dolan TF; Hunter CA; Laakso T; Sjöholm I; Stjärnkvist P
    J Pharm Pharmacol; 1987 Oct; 39(10):832-5. PubMed ID: 2891821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse.
    Carter KC; Alexander J; Baillie AJ; Dolan TF
    Exp Parasitol; 1989 May; 68(4):375-81. PubMed ID: 2542078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent.
    Carter KC; Baillie AJ; Alexander J; Dolan TF
    J Pharm Pharmacol; 1988 May; 40(5):370-3. PubMed ID: 2899637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
    Mullen AB; Baillie AJ; Carter KC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS; Farrell JP
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R; Roychoudhury J; Palit P; Ali N
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antimony content of the thyroid of man and animals undergoing visceral leishmaniasis treatment with the organic compound of antimony, stibogluconate sodium].
    Fuzaĭlov IuM
    Med Parazitol (Mosk); 1982; 51(1):62-5. PubMed ID: 6278277
    [No Abstract]   [Full Text] [Related]  

  • 18. The distribution of free and non-ionic vesicular sodium stibogluconate in the dog.
    Collins M; Carter KC; Baillie AJ; O'Grady J
    J Drug Target; 1993; 1(2):133-42. PubMed ID: 8069551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
    Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate.
    Baillie AJ; Coombs GH; Dolan TF; Laurie J
    J Pharm Pharmacol; 1986 Jul; 38(7):502-5. PubMed ID: 2875149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.